An Array co-founder re-emerges as CEO of a small academic spinout, looking to remake an old class of cancer drugs
Tony Piscopio hadn’t worked as a bench scientist in years when, around 2011, he got put in touch with a team at the University of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
